Tecemotide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Tecemotide
Accession Number
DB12568
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

Tecemotide has been used in trials studying the treatment of Prostate Cancer and Carcinoma, Non-Small-Cell Lung.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
Categories
UNII
Q7Y026G2CX
CAS number
221214-84-2

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Tecemotide.
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Tecemotide.
2-MethoxyethanolThe therapeutic efficacy of Tecemotide can be decreased when used in combination with 2-Methoxyethanol.
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Tecemotide.
6-Deoxyerythronolide BThe therapeutic efficacy of Tecemotide can be decreased when used in combination with 6-Deoxyerythronolide B.
9-(N-methyl-L-isoleucine)-cyclosporin AThe therapeutic efficacy of Tecemotide can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Abatacept.
AbetimusThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Abetimus.
AbituzumabThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Abituzumab.
Acetyl sulfisoxazoleThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Acetyl sulfisoxazole.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911345
Wikipedia
Tecemotide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasms, Lung2
2CompletedTreatmentMultiple Myeloma (MM)1
2CompletedTreatmentProstate Cancer1
2CompletedTreatmentRectal Carcinoma1
3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3TerminatedTreatmentCancer, Breast1
3TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
Not AvailableTerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Multiple Myeloma (MM)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 16:55 / Updated on October 01, 2018 15:17